P2Y₁₂ Receptor Inhibitors: Integrating Ticagrelor Into the Management of Acute Coronary Syndrome

Creator(s)

Michael A. Crouch, East Tennessee State University
Vince J. Colucci, University of Montana
Patricia A. Howard, University of Kansas Medical Center
Sarah A. Spinler, Philadelphia College of Pharmacy

Document Type

Note

Publication Date

9-1-2011

Description

Acute coronary syndrome (ACS) is a continuum of disease that includes non-ST-segment elevation ACS and ST-segment elevation myocardial infarction. The purpose of this article is to define the developing role of ticagrelor in ACS and compare it to currently available P2Y12 receptor inhibitors. While clopidogrel remains the "workhorse" P2Y12 receptor inhibitor for many patients with ACS and prasugrel has an established role in select situations, clinicians must now assimilate the evolving role of ticagrelor. Although ticagrelor offers important advances in the management of ACS (eg, reversibility), there are also notable clinical considerations (eg, unique adverse effects such as dyspnea). Based on the current evidence, we propose an algorithm to aid clinicians in the selection of a P2Y12 receptor inhibitor for patients with ACS in various clinical situations.

Citation Information

Crouch, Michael A.; Colucci, Vince J.; Howard, Patricia A.; and Spinler, Sarah A.. 2011. P2Y₁₂ Receptor Inhibitors: Integrating Ticagrelor Into the Management of Acute Coronary Syndrome. Annals of Pharmacotherapy. Vol.45(9). 1151-1156. https://doi.org/10.1345/aph.1Q141 PMID: 21852599 ISSN: 1060-0280